Clinical trials: Tislelizumab
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
NK/T Cell Lymphoma
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT)…
- Trial name
- NCT04899414
- Testing
- Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University
Resectable Non-Small-Cell Lung Cancer
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
This study aims to explore the efficacy and safety of thymosin α-1 (Tα1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer
- Trial name
- NCT06607926
- Testing
- Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xuanwu Hospital, Beijing
Hepatocellular Carcinoma (HCC)
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
The system assesses the heterogeneity of HCC patients in terms of therapeutic outcomes (such as rwPFS, ORR, PRO) and adverse reactions during the process of interventional therapy combined with systemic treatment.
- Trial name
- NCT07156617
- Testing
- Interventional therapy, Systemic therapy
- Where
- 14 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Xuhua Duan
Extensive-stage Small-cell Lung Cancer
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive…
- Trial name
- NCT06536868
- Testing
- Tislelizumab, Etoposide, Carboplatin or Cisplatin
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Hospital of Shanxi Medical University
Lymph Node Metastasis, Neurovascular Invasion
Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）
The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can…
- Conditions
- Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection
- Trial name
- AICRC (NCT06997913)
- Testing
- Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hengchao Yu
Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
Preoperative Immune checkpoint inhibitors combined with chemotherapy have revolutionized the treatment landscape of locally advanced esophageal squamous cell carcinoma.
- Conditions
- Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy
- Trial name
- PICCRT (NCT05596890)
- Testing
- Paclitaxel-albumin, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Provincial People's Hospital
Advanced Solid Tumors
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with…
- Trial name
- NCT07185243
- Testing
- recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
Advanced Solid Tumor
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab.
- Trial name
- IMMINENT-01 (NCT05840835)
- Testing
- IMX-110 combined with Tislelizumab
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Immix Biopharma, Inc.
NK/T Cell Lymphoma
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
The goal of this clinical trial is to learn if the regimen of dexamethasone, azacitidine, pegaspargase and tislelizumab (DAPT regimen) combined with radiotherapy works to treat stage I or II NK/T cell lymphoma in adults.
- Trial name
- NCT07000617
- Testing
- DAPT regimen plus radiotherapy
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Cancer
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2…
- Trial name
- NCT06749860
- Testing
- Disitamab Vedotin + tislelizumab + bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Esophageal Neoplasms
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
According to the Global Burden of Disease Study, the number of esophageal cancer cases globally increased from 319,969 in 1990 to 534,563 in 2019, a relative increase of 67.07 per cent.
- Trial name
- SJZ-RMEEC01 (NCT06646588)
- Testing
- Fruquintinib, Tislelizumab, Radiotherapy
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Hebei Medical University Fourth Hospital
Cervical Squamous Cell Carcinoma
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
The goal of this clinical trail is to investigate the efficacy and safety of PD-1 antibody Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for patients diagnosed as local advanced cervical…
- Trial name
- TiTanec (NCT05013268)
- Testing
- Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Colorectal Neoplasms Malignant
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan（group A） compared to third-line regimens selected by researchers（group B） in…
- Trial name
- NCT05278351
- Testing
- Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Zhongshan Hospital
Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a…
- Trial name
- NCT07523737
- Testing
- Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Beijing Tongren Hospital
Triple Negative Breast Cancer
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and…
- Trial name
- AdvanTIG-211 (NCT05809895)
- Testing
- Ociperlimab, Tislelizumab, Paclitaxel
- Sponsor
- Novartis Pharmaceuticals
Esophagus Cancer
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Trial name
- NCT05807542
- Testing
- Tislelizumab, Paclitaxel-albumin, Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic…
- Trial name
- NCT05917431
- Testing
- SBRT plus tislelizumab and regorafenib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Solid Tumor Cancer
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in…
- Trial name
- LM364 (NCT07847905)
- Testing
- LM-364 for injection, Tislelizumab
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- LaNova Medicines Limited
Initially Unresectable Hepatocellular Carcinoma
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular…
- Trial name
- NCT07480382
- Testing
- Liver Venous Deprivation (LVD), Conventional Transarterial Chemoembolization(C-TACE), Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hong Wu